Particularities of infectious complications in systemic lupus erythematosus

##plugins.themes.academic_pro.article.sidebar##

Published Nov 24, 2023
Download
pdf
Vol. 101 No. 11 (2023): Tunis Med nov

##plugins.themes.academic_pro.article.main##

Ines Naceur
Department of Internal Medicine , La Rabta Hospital, Faculty of Medicine of Tunis , University of Tunis El Manar, Tunis, Tunisia
Sahar Skhiri
Department of Internal Medicine , La Rabta Hospital, Faculty of Medicine of Tunis , University of Tunis El Manar, Tunis, Tunisia
Tayssir Ben Achour
Department of Internal Medicine , La Rabta Hospital, Faculty of Medicine of Tunis , University of Tunis El Manar, Tunis, Tunisia
Fatma Said
Department of Internal Medicine , La Rabta Hospital, Faculty of Medicine of Tunis , University of Tunis El Manar, Tunis, Tunisia
https://orcid.org/0000-0001-7352-8381
Monia Smiti
Department of Internal Medicine , La Rabta Hospital, Faculty of Medicine of Tunis , University of Tunis El Manar, Tunis, Tunisia
Imed Ben Ghorbel
Department of Internal Medicine , La Rabta Hospital, Faculty of Medicine of Tunis , University of Tunis El Manar, Tunis, Tunisia
Mohamed Habib Houman
Department of Internal Medicine , La Rabta Hospital, Faculty of Medicine of Tunis , University of Tunis El Manar, Tunis, Tunisia

Abstract

Aim: To describe characteristics of systemic lupus erythematosus (SLE) patients with infectious complications and to determine frequency, clinical and microbiological  features and outcomes of reported infections.


Methods: This is a descriptive, retrospective study conducted over an 11-year period at the Internal Medicine Department La Rabta Hospital Tunis, collecting medical records of SLE patients who had experienced infectious complications.


Results: Fifty-six patients were included, consisting of 52 females and 4 males (gender ratio M/F= 0.07). The mean age at SLE diagnosis was 35±13.8 years. The mean duration of the disease was 4.8±3.1 years. A total of seventy-eight infections were documented. Infection revealed the disease in 12 patients (21%) and occurred after an average delay of 36 months [1-156 months] of SLE diagnosis. Forty-three patients (74%) were receiving corticosteroid therapy, associated in 37.5% of cases with immunosuppressive treatment. Urinary and pleuro-pulmonary infections were most common infectious sites. An infectious agent was identified in 59 cases (76%). Bacterial infections were the most common (76%), dominated by the enterobacteria pathogen agent. Viral infections (n=12) were mainly caused by varicella-zoster virus and cytomegalovirus. Five patients required intensive care. Twenty patients experienced a lupus flare during the infectious episode. The outcome was favorable in 52 (93%) patients. Three patients died, two due to septic shock caused by pulmonary infection in two cases and cutaneous infection in one patient. One patient died from a probable pulmonary embolism.


Conclusion: Infectious complications are responsible for significant morbidity and mortality during SLE. Hence the .... (abstract truncated at 250 words)

Keywords:

systemic lupus erythematosus, infections

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Jung JY, Suh CH. Infection in systemic lupus erythematosus, similarities, and differences with lupus flare. Korean J Intern Med. 1 mai 2017;32(3):429‑38.
  2. Goldblatt F, Chambers S, Rahman A, Isenberg D. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus. juill 2009;18(8):682‑9.
  3. Wang Z, Wang Y, Zhu R, Tian X, Xu D, Wang Q, et al. Long-term Survival and death causes of systemic lupus erythematosus in China: A systemic review of observational studies. Medicine. mai 2015;94(17):e794.
  4. Petri M. Infection in systemic lupus erythematosus. Rheumatic Disease Clinics of North America. mai 1998;24(2):423‑56.
  5. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism. sept 1997;40(9):1725‑1725.
  6. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis & Rheumatism. août 2012;64(8):2677‑86.
  7. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey‐Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. sept 2019;71(9):1400‑12.
  8. Kiriakidou M, Ching CL. Systemic lupus erythematosus. Annals of Internal Medicine. 2 juin 2020;172(11):ITC81‑96.
  9. Zonana-Nacach A, Camargo-Coronel A, Yañez P, Sánchez L, Jimenez-Balderas FJ, Fraga A. Infections in outpatients with systemic lupus erythematosus: a prospective study. Lupus. juill 2001;10(7):505‑10.
  10. Shyam C, Malaviya AN. Infection-related morbidity in systemic lupus erythematosus: A clinico-epidemiological study from Northern India. Rheumatol Int. janv 1996;16(1):1‑3.
  11. Gladman DD, Hussain F, Iban D, Urowitz MB. The nature and outcome of infection in systemic lupus erythematosus. Lupus. avr 2002;11(4):234‑9.
  12. Costa-Reis P, Nativ S, Isgro J, Rodrigues T, Yildirim-Toruner C, Starr A, et al. Major infections in a cohort of 120 patients with juvenile-onset systemic lupus erythematosus. Clin Immunol. déc 2013;149(3):442‑9.
  13. Noel V. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis. 1 déc 2001;60(12):1141‑4.
  14. Ng WL, Chu CM, Wu AKL, Cheng VCC, Yuen KY. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. QJM. 1 janv 2006;99(1):37‑47.
  15. Jallouli M, Frigui M, Marzouk S, Mâaloul I, Kaddour N, Bahloul Z. Complications infectieuses au cours du lupus érythémateux systémique : étude de 146 patients. Rev Med Interne. août 2008;29(8):626‑31.
  16. Teh CL, Wan SA, Ling GR. Severe infections in systemic lupus erythematosus: disease pattern and predictors of infection-related mortality. Clin Rheumatol. août 2018;37(8):2081‑6.
  17. Herrinton LJ, Liu L, Goldfien R, Michaels MA, Tran TN. Risk of Serious Infection for Patients with Systemic Lupus Erythematosus Starting Glucocorticoids with or without Antimalarials. J Rheumatol. août 2016;43(8):1503‑9.
  18. Michel M, Godeau B. Complications infectieuses des maladies systémiques. Réanimation . nov 2005;14(7):621‑8.
  19. Singh BK, Singh S. Systemic lupus erythematosus and infections. Reumatismo. 19 nov 2020;72(3):154‑69.
  20. Mohamed DF, Habeeb RA, Hosny SM, Ebrahim SE. Incidence and risk of infection in egyptian patients with systemic lupus erythematosus. Clin Med Insights Arthritis Musculoskelet Disord. janv 2014;7:CMAMD.S15346.
  21. Battaglia M, Garrett-Sinha LA. Bacterial infections in lupus: Roles in promoting immune activation and in pathogenesis of the disease. J Transl Autoimm. 2021;4:100078.
  22. Sciascia S, Cuadrado MJ, Karim MY. Management of infection in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. juin 2013;27(3):377‑89.
  23. Schurder J, Goulenok T, Jouenne R, Dossier A, Van Gysel D, Papo T, et al. Pneumococcal infection in patients with systemic lupus erythematosus. Joint Bone Spine. mai 2018;85(3):333‑6.
  24. Abramson S, Kramer SB, Radin A, Holzman R. Salmonella bacteremia in systemic lupus erythematosus. Eight-year experience at a municipal hospital. Arthritis Rheum. janv 1985;28(1):75‑9.
  25. Muhammed H, Jain A, Pattanaik SS, Chatterjee R, Naveen R, Kabeer H, et al. Clinical spectrum of active tuberculosis in patients with systemic lupus erythematosus. Rheumatol Int. déc 2021;41(12):2185‑93.
  26. Borba EF, Ribeiro ACM, Martin P, Costa LP, Guedes LKN, Bonfá E. Incidence, risk factors, and outcome of herpes zoster in systemic lupus erythematosus. JCR. avr 2010;16(3):119‑22.
  27. Chabert P, Hot A. Infection à cytomégalovirus au cours du lupus érythémateux systémique. Série de 12 cas cliniques et revue de la littérature. Rev Med Interne. avr 2021;42(4):237‑42.
  28. Bosch X, Guilabert A, Pallarés L, Cervera R, Ramos-Casals M, Bové A, et al. Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus. sept 2006;15(9):584‑9.
  29. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003 Sep;82(5):299-308. doi: 10.1097/01.md.0000091181.93122.55. PMID: 14530779.
  30. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol. juill 1995;22(7):1265‑70.
  31. Dhital R, Pandey RK, Poudel DR, Oladunjoye O, Paudel P, Karmacharya P. All-cause hospitalizations and mortality in systemic lupus erythematosus in the US: results from a national inpatient database. Rheumatol Int. mars 2020;40(3):393‑7.
  32. Al‐Adhoubi NK, Al‐Balushi F, Al Salmi I, Ali M, Al Lawati T, Al Lawati BSH, et al. A multicenter longitudinal study of the prevalence and mortality rate of systemic lupus erythematosus patients in Oman: Oman Lupus Study. Int J Rheum Dis. juin 2021;24(6):847‑54.
  33. Olivier Meyer, Anti-CRP antibodies in systemic lupus erythematosus, Joint Bone Spine, 2010 ; 77(5) :384-89.
  34. Kim HA, Jeon JY, An JM, Koh BR, Suh CH. C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. J Rheumatol. 2012 Apr;39(4):728-34.
  35. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(4):R109.